BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 22, 2010
 |  BioCentury  |  Product Development

Cara's No-Brainer Opioid Solution

Cara Therapeutics Inc. believes its CR845 kappa opioid agonist will fare better than others because the peptide is too large to cross the blood-brain barrier, meaning it should avoid the side effects and narrow therapeutic windows associated with CNS receptor activation.

The company presented data from a Phase II trial to treat acute post-operative pain earlier this month, showing CR845 met the co-primary endpoint of pain reduction 4-8 hours after dosing.

Standard of care for post-operative pain is multi-modal analgesia, which includes a mu opioid receptor (OPRM1; MOR) agonist such as morphine or fentanyl as the backbone. But because mu opioids activate receptors in the brain, their side effects include nausea, vomiting, sedation, respiratory depression and abuse.

President and CEO Derek Chalmers believes CR845 may reduce the need for morphine and in...

Read the full 656 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >